Home
Traws Pharma

七月 2026的Traws Pharma市场份额分析

Targeting escape mutations in hematological cancers with first and best in class medicines.

行业: 不适用

域trawspharma.com

成立年份--

员工51 - 200

年营收--

Traws Pharma

Traws Pharma（包含公司地区分支机构）

trawspharma.com

查看更多网站流量和参与度信息

Traws Pharma热门域名的总访问量

了解Traws Pharma市场份额和潜在市场覆盖范围。

过去 3 个月的总访问量

子公司明细

trawspharma.com4.4K

使用销售情报查看更多信息

Traws Pharma热门域名的平均访问时长

分析Traws Pharma参与度指标。

过去 3 个月的平均访问时长

子公司明细

trawspharma.com00:00:48

使用销售情报查看更多信息

Traws Pharma热门域名的平均页面浏览量

了解Traws Pharma如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。

过去 3 个月的平均页面浏览量

子公司明细

trawspharma.com2.05

使用销售情报查看更多信息

Traws Pharma 排名靠前的竞争对手（按域名）

似乎没有足够的数据。

无数据可显示

Traws Pharma 采用的主要技术

这些是排名前 Traws Pharma 的顶级域名所使用的网站技术（按行业分列）

付款和货币 (3)

Cart Functionality

转化和分析 (2)

Google Analytics

电子商务 (2)

Swap

电子邮件服务 (2)

G Suite

更多技术

7

查看全部

Traws Pharma 的新闻与信号

借助 Similarweb 销售信号提醒，每当在目标受众之中出现新的机会或威胁时，您都会收到所识别出购买信号的每日更新。

新闻Traws Pharma, Inc. is developing broad-spectrum antiviral combination therapy on May 27th '26.Traws Pharma Inc. said May 27 that it is advancing development of a proprietary broad-spectrum antiviral combination therapy aimed at combating deadly viruses, including Hantavirus, Ebola, and Lassa fever.

新闻Traws Pharma, Inc. is developing therapy for the Hantaan strain of hantavirus on May 11th '26.Traws Pharma, which is developing a therapy for the Hantaan strain of hantavirus, jumped 7% in early Monday trading before ending the day down 7%, though it remains up 34% over the past five days.

新闻Traws Pharma, Inc. received financing of $10M on Apr 15th '26.NEWTOWN, Pa., April 15, 2026 (GLOBE NEWSWIRE) - Traws Pharma, Inc. (NASDAQ: TRAW, "Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced that it has entered into a securities purchase agreement with new and existing institutional and accredited investors for a private investment in public equity ("PIPE") financing expected to provide approximately $10.0 million in gross proceeds at closing.